my personal edition > asthma > news
E-Mail this DGNews to a colleague
DGNews
Asthma and COPD Patients Highly Satisfied With Handling and Inhalation from New Generation Soft Mist Inhaler
MUNICH, GERMANY -- September 12, 2006 -- The results of an observational study presented at the 16th Annual Congress of the European Respiratory Society in Munich, Germany show that patients with asthma and chronic obstructive pulmonary disease (COPD) are highly satisfied with the novel RespimatŪ Soft Mist Inhaler (SMI) from Boehringer Ingelheim.
In a 12 week observational cohort study in respiratory specialist practices in Germany, the handling, including device assembly, inhalation satisfaction and technique were assessed with a clinical questionnaire. 2006 patients from 695 centres in Germany were interviewed after 4, 8 and 12 weeks of 2-4 times daily administration of ipratropium bromide/fenoterol 20/50 mcg in the RespimatŪ Soft Mist Inhaler (BDR). Most patients (66%) received treatment with the Soft Mist Inhaler for the first time.
After 4 weeks, feedback from both physicians and patients was very positive. 79% of patients and 87% of physicians were very satisfied or satisfied with the ease of the set-up for use of the Soft Mist Inhaler. Reactions to the soft mist inhalation were even more positive: 92% of patients and 97% of physicians were very satisfied or satisfied. The rating for the inhalation technique was also high: 86% of patients and 91% of physicians were very satisfied or satisfied. The ratings improved further over time.
Overall, most patients (74%) and physicians (75%) rated the treatment of ipratropium bromide/fenoterol from the Soft Mist Inhaler as better or much better than their previous treatment.
RespimatŪ Soft Mist Inhaler
Boehringer Ingelheimīs RespimatŪ Soft Mist Inhaler is a propellant-free, novel inhaler that generates a slow-moving, long-lasting cloud (the Soft Mist) with a high fine particle fraction (less than 5.8 mcm). The Soft Mist travels more slowly and lasts much longer than aerosol clouds from traditional devices. Scintigraphic studies have shown that these properties improve the deposition of drug in the lungs and produce less deposition in mouth and throat than the pressurised metered dose inhaler (pMDI).
SOURCE: Boehringer Ingelheim GmbH
All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.
| 
